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Abstract 
  
 Normal tension glaucoma is a disease that causes glaucomatose damage to the 
optic nerve without the presence of elevated intraocular tensions. New studies have 
emerged that shine a new light on possible pathologic mechanisms and present new 
therapeutic approaches to this disease. We present an inclusive literature review, 
focusing on these new developments, comparing them with older notions and 
treatments, and discussing epidemiology data and diagnostic methods. 
 
 
Resumo 
  
 O Glaucoma de Tensão Normal é uma patologia que provoca alterações 
glaucomatosas no nervo óptico sem se constatar pressões intraoculares elevadas. Têm 
surgido novos estudos científicos que lançam um novo olhar sobre os possíveis 
mecanismos fisiopatológicos e apresentam novas estratégias terapêuticas para esta 
doença. Apresentamos uma revisão da literatura inclusiva, abordando estas novas 
noções, comparando-as com postulados e tratamentos anteriores, e discutindo dados 
epidemiológicos e métodos de diagnóstico. 
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Introduction 
  
 In 1857, Albrecht von Graefe, a German ophthalmologist, recognised and 
described for the first time glaucomatous optic neuropathy in the setting of 
physiologic intraocular pressure (IOP). Since then, scientists and ophthalmologists 
have been discussing whether Normal Tension Glaucoma (NTG) is just a part of the 
spectrum of Primary Open-Angle Glaucoma (POAG) or an entirely different disease, 
with a distinct pathophysiology. Recent studies have suggested new theories on the 
development of this disease that may open doors to alternative therapies in the 
treatment of, not only NTG, but also all types of glaucoma. 
 
 Review methods and selection process 
  
 Literature was searched through the following methods: 
 a) Using the following keywords in the Google Scholar search engine: 
"normal tension glaucoma", "normal tension glaucoma pathophysiology", "normal 
tension glaucoma epidemiology", "normal tension glaucoma treatment", "normal 
tension glaucoma associated disorders", among others. 
 b) Similar papers suggestions by Google Scholar and Pubmed, according to 
tittle and abstract relevance. 
 c) Reading Ophtalmology text books (Shaarawy, Sherwood, Hitchings, & 
Crowston, 2015) 
 d) Consulting Medscape's webpage concerning normal tension glaucoma 
(Freudenthal, 2014) 
 The selection of the articles was made according to the study pertinence and 
statistic significance. Preference was given to articles published in the last 10 years, 
with inclusion of pertinent or historically important papers.  
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 Epidemiology 
  
 NTG is fairly infrequent in European and American populations but is very 
common in Eastern Asia. A study based on an American population found that Asian 
Americans have a 51% increased hazard of Open-Angle Glaucoma (OAG), a 123% 
increased risk of developing closed-angle glaucoma and a 159% increased probability 
of having NTG, compared with non-Hispanic whites (Stein et al., 2011). In fact, NTG 
is the most common type of open-angle glaucoma in Japan: the prevalence of POAG 
in this population is calculated to be around 3.9%, with 92% of these patients having 
IOP less than 21 mmHg (Iwase et al., 2004). Similar incidences were found in a study 
of a selected Korean population (C. S. Kim, Seong, Lee, & Song, 2011).  
 
 Pathophysiology 
  
 NTG is a multifactorial chronic optic neuropathy that features characteristics 
similar to POAG, except for high IOP, the values of which are consistently under 23 
mmHg (M. Kim, Kim, Park, & Kim, 2012). Diagnostic criteria can be defined as (1) 
the presence of open iridocorneal angles, (2) untreated IOP less than 21mmHg in 
multiple measures, (3) progressive changes in either visual fields or optic nerve 
cupping and (4) absence of other causes of optic neuropathy. (Tezel, Kass, Kolker, & 
Wax, 1996). The clinical appearance of the optic nerve damage, through 
ophthalmoscopy, is no different between POAG and NTG (Tezel et al., 1996). 
However, the absence of an abnormal IOP suggests dissimilar pathological 
development. 
 a) Increased susceptibility to high intraocular pressure 
 
 IOP, though within normal values, may be nevertheless important to the 
progression of NTG, as demonstrated by the fact that medical therapy which lowers 
IOP slows the progression of glaucomatose neuropathy even in NTG (Colaborative 
Normal-Tension Glaucoma Study Group, 1998). 
 IOP values in NTG are often higher than reference values for a healthy 
population, while still being under 21mmHg (M. Kim et al., 2012). Corneal hysteresis 
and corneal resistance factor are significantly lower in NTG (Grise-Dulac et al., 2011; 
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Morita, Shoji, Kamiya, Fujimura, & Shimizu, 2012). Since biomechanical properties 
of the cornea reflect those of the eyeball as a whole, there may exist an increased 
susceptibility to high IOP in NTG patients related to deformities in the eyeball itself. 
 b) Metabolic damage caused by vascular dysfunction 
 
 Other factors may be of great importance in NTG development besides IOP. 
In POAG, increased IOP exerts an abnormal mechanical stress on the optic nerve, 
leading to mechanical damage of glial astrocytes in the optical nerve head, their 
incapability to support the metabolism of axons and, ultimately, the death of retinal 
ganglion cells (Dai et al., 2012). In NTG the same damage to astrocytes may exist but 
due to metabolic damage rather than mechanical stress.  
 It has been theorized that an association between systemic vascular 
dysfunctions and NTG exists (Flammer, Konieczka, & Flammer, 2013). Vascular 
dysregulation, a term that embraces arterial spasms, and inappropriate constrictions 
and dilatations of arteries, veins or capillaries, can affect any organ, including the eye 
(Flammer et al., 2013). The progression of glaucomatose visual field damage in 
POAG correlates with altered retrobulbar hemodynamic variables, such as low 
baseline blood flow velocities and high baseline resistivity in the central retinal artery 
(Satilmis, Orgül, Doubler, & Flammer, 2003). When comparing nocturnal systemic 
blood pressure variability, peripheral arterial stiffness, carotid intima-media thickness, 
and ocular perfusion pressure between POAG patients, NTG patients and healthy 
controls, one reaches the conclusion that patients with POAG or NTG exhibit similar 
changes in ocular and systemic circulation in the early stages of their disease process, 
which are not present in controls (Mroczkowska, 2012).  Also, early stage, newly 
diagnosed, NTG patients showed signs of sub-clinical vascular abnormalities at both 
macro and microvascular levels (Mroczkowska et al., 2012). Another study found 
NTG patients exhibited a shift towards sympathetic activity when several variables 
related to sympathovagal balance were analysed. Such imbalance may result in 
increased vascular resistance and may have circulatory implications (Wierzbowska, 
Wierzbowski, Stankiewicz, Siesky, & Harris, 2012). Nocturnal blood pressure 
dipping and greater variation of ocular perfusion pressure were as well found in NTG 
patients (Choi et al., 2013; Ramli, Nurull, Hairi, & Mimiwati, 2013). All these studies 
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suggest that some degree of isquemia in the optic nerve has importance in NTG (and 
to some degree, POAG) pathophysiology. 
 Obstructive sleep apnea syndrome is a disease characterized by repetitive 
upper airway obstructions during sleep, inducing hypoxia and sleep disruption. There 
is  a high prevalence of sleep apnea syndrome in normal-tension glaucoma patients. 
(Bilgin, 2014; Mojon et al., 2002). The direct pathological link between sleep apnea 
syndrome and NTG is not yet established, but one can hypothesise that the disease 
causes glaucomatous damage to the optic nerve by means of hypoxia and vascular 
dysregulation (Gutiérrez-Díaz, Pérez-Rico, de Atauri, Mencía-Gutiérrez, & Blanco, 
2012; Lin et al., 2011) 
 c) Metabolic damage caused by autoimmunity 
  
 There is also scientific evidence that favours a role for autoimmunity in 
glaucoma development. Many molecules overexpressed in autoimmune diseases are 
also raised in glaucoma (POAG and NTG) patients, such as TNF-alpha, matrix 
metalloproteinases, interleukin 6 and others (Wax, 2011). However, despite this 
evidence, it is still difficult to establish a clear pathophysiologic link between these 
measurements and glaucoma, though it can be theorised that, if autoimmunity has a 
role in glaucoma, it may be responsible for initiating a cascade of events similar to 
those that happen with vascular injury. 
 In short, vascular dysfunction as well as autonomic dysfunction can lead to a 
poor blood perfusion to the ocular tissues, including the optic nerve. This, as with 
autoimmunity, may cause a rise in oxidative stress and a subsequent release of 
inflammation mediators, activation of astrocytes, a raise of glutamate levels and 
damage to retinal ganglion cells. 
 
 Diagnostic procedures and workup 
 
 The diagnosis of NTG is made when optic disc cupping and glaucomatous 
visual field defects are found in conjunction with normal IOP. (Sheleg, 2011). 
However, other pathologies should be excluded. Therefore, some diagnostic 
procedures are necessary.  
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 a) History 
 
 Careful history should be taken. The ophthalmologist should inquire about 
episodes of ocular pain, which may indicate previous acute angle closure attack, and 
other probable causes of optic nerve damage, such as trauma, uveitis and steroid 
treatment. The use of systemic medication that lowers IOP, as beta-blocker, should be 
assessed. Glaucomatous damage in spite of low IOP measurements may result from 
low compliance, in patients that only take anti-glaucoma medications before their e 
medical examinations. 
 Blood pressure, ischemic vascular disease, perfusion pressure, vasospastic 
disorders (migraine, Raynaud phenomenon) and obstructive sleep apnea are 
conditions associated with NTG and should therefore be assessed in selected cases. 
 b) Ophthalmologic exam  
 
 To begin with, ocular hypertension as well as POAG must be excluded, by 
measurement of IOP. A diurnal curve of IOP should be performed. IOP values should 
be inferior to 21 mmHg throughout the day.  
 The anterior chamber should be analysed. NTG has an open, normal appearing 
angle. Angle closure and angle recession should therefore be excluded.  
 Corneal thickness is thinner in NTG (Copt, Thomas, & Mermoud, 1999) and 
can be measured by ultrassound pachymetry. Pachymetry is also useful to adjust the 
difference between measured IOP by Goldman tonometry and true IOP (Morita et al., 
2010). Keratic precipitates point to a uveitis diagnosis and Krukenberg spindle 
indicate pigment dispersion.  
 Glaucomflecken in the lens point to previous IOP elevation, usually secondary 
to acute angle closure. If present, NTG is excluded. 
 Refractive errors should be measured and considered as well.  
 Ocular fundus in NTG is grossly similar to POAG. However, some authors 
describe differences in disc optic appearance, such as greater thinning of neuroretinal 
rim of the disc was found in NTG (Caprioli & Spaeth, 1985). Optic disc 
haemorrhages can be found in both NTG and POAG patients, are very rarely found in 
healthy eyes (Bengtsson, 1990) and are a risk factor for progression of visual field 
defects in NTG (Drance, Anderson, & Schulzer, 2001). Disc haemorrhages are 
usually splinter or flame-shaped hemorrhages perpendicular to the optic disc border.  
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 c) Blood tests 
 
 Erythrocyte sedimentation rate (ESR) is a useful tool in cases of decreased 
central acuity with a pale nerve to rule out anterior ischemic optic neuropathy 
(AION). 
 Syphilis can cause glaucomatous features. As such, rapid plasma reagent 
(RPR) and fluorescein treponema antibody (FTA) should be ordered to rule out ocular 
syphilis. 
 Given the connection between NTG and autoimmune diseases, it is 
recommended to rule them out by testing for the presence of antinuclear antibodies 
(ANA). 
 d) Complementary diagnostic exams 
 
 Optical coherence topography (OCT) is a helpful exam in the diagnosis and 
monitoring of glaucomatous optic neuropathy. Optic nerve head and retinal nerve 
fiber should be analysed. 
 When visual-field defects first present, especially when a marked asymmetry 
is present, or there is a rapid progression of neuropathy, a referral to a 
neurophtalmologist and magnetic resonance imaging are to be considered.  
 Carotid Doppler testing is recommended in patients with suspected 
atherosclerosis to rule out carotid insufficiency. 
 A 24-hour blood pressure monitoring is also recommended, given the 
association of NTG with nocturnal hypotension.  
 
 Treatment 
 
 The fact that IOP, even within normal statistical values may be a contributing 
factor to optic nerve damage has led ophthalmologists to treating NTG as one does in 
POAG, i.e. by lowering IOP, through medical and surgical methods. 
 a) Pharmacological control of IOP 
 
 Since the 1998 study by the Colaborative Normal-Tension Glaucoma Study 
Group, the accepted goal for NTG medical treatment has been to lower IOP by 30% 
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(Colaborative Normal-Tension Glaucoma Study Group, 1998). Recent literature is 
revising this idea, adding that lowering IOP just by 10,6% has a significant effect in 
stopping nerve damage progression and that the most important goal is to maintain 
stable IOP values (Komori, Ishida, & Yamamoto, 2014). Latanoprost, bimatoprost, 
timolol and brimonidine are the most effective drugs when considering the percentage 
of IOP reduced in NTG patients (Cheng, Cai, & Wei, 2009). Brimonidine in particular 
lowers IOP as effectively as timolol but has demonstrated better results as far as 
preserving visual field (Krupin, Liebmann, Greenfield, Ritch, & Gardiner, 2011). This 
is related to the fact that brimonidine improves vascular regulation in NTG (Feke et 
al., 2014).  
 b) Surgical control of IOP 
 
 Surgical procedures have been used in POAG as an alternative to 
pharmacological therapies in order to lower IOP. There is a small amount of studies 
focusing on their use in NTG. 
 Use of Argon Laser trabeculoplasty (ALT) in NTG resulted in IOP reductions 
lasting up to 21.6 months. However, ALT caused scarring that prevented repeating the 
procedure once the laser effect worn off. (Schwartz AL, Perman KI, 1984) 
 Selective Laser Trabeculoplasty (SLT) has been the focus of newer studies 
regarding NTG. It has been shown that it reduces mean intraocular pressure as well as 
intraocular pressure variation (El Mallah, Walsh, Stinnett, & Asrani, 2010). A recent 
study demonstrated that the effect persists at least until years after the surgery, with an 
average of 12% of treated eyes showing IOP reduction, with 41% fewer medication, 
whereas 11% of treated eyes were medication free (Lee, Shum, Chan, & Lai, 2015). 
Further research is needed concerning this treatment option, especially related to the 
way surgical procedures impact on the progression of the disease. 
 c) New therapies 
 
 Recently, new approaches to NTG treatment have been suggested.  
 Some authors argue that increasing ocular perfusion pressure (OPP) may have 
a positive effect in NTG. For one, anti-hypertensive treatment in patients with 
systemic hypertension should be reduced in order to prevent very low OPPs 
(Cherecheanu, Garhofer, Schmidl, Werkmeister, & Schmetterer, 2013). Second, 
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pharmaceutical therapy to raise OPP should be considered. An increase in daily salt 
consumption or fludrocortisone therapy have been suggested in order to raise 
systemic blood pressure and reduce nocturnal blood pressure dipping (Mozaffarieh & 
Flammer, 2007, 2013). This doesn't seem to be a viable option considering the co-
morbidities associated with high systemic blood pressure such as stroke, myocardial 
infarction, vascular disease, and chronic kidney disease. As stated above, brimonidine 
may have a role in regulating local vascular flow (Feke et al., 2014). Similarly, 
nifedipine, as a calcium-channel blocker, has been suggested in order to improve 
ocular blood flow (Harris, Evans, Cantor, & Martin, 1997). 
 Many authors have proposed Gingko biloba as a new neuroprotective therapy. 
Pharmacologically, Gingko biloba targets the factors involved in glaucomatous 
disease (disturbed ocular microcirculation, oxidative stress, impairment of 
mitochondrial function in the retinal ganglion cells): Gingko biloba has antioxidative 
effects, stabilizes the mitochondria, has anti-inflammatory effects, regulates 
microcirculation and has antithrombotic, vasorelaxative and antivasospastic 
properties. Therefore, theoretically, Ginkgo biloba could be beneficial for glaucoma 
(Cybulska-Heinrich, Mozaffarieh, & Flammer, 2012; Shim, Kim, Choi, Kim, & Park, 
2012). It has been used recently by clinicians as adjuvant therapy for NTG, in 
addition to tension-lowering drugs (Cybulska-Heinrich et al., 2012; Mozaffarieh & 
Flammer, 2007).  
 d) The future of NTG therapy 
 
 Murine models of NTG have been used to test the neuroprotective effects of 
known neurologic active drugs. Valproic acid, for instances, was shown to supress 
retinal degradation, ameliorate deterioration in visual function, reduce the oxidative 
stress level and stimulate retinal cell survival signalling in mice with deletion of 
glutamate transporter genes glutamate/aspartate transporter (GLAST KO), a murine 
model for normal tension glaucoma (Kimura et al., 2015). This means that a 
commonly used drug with known safety profiles, such as valproic acid may be of 
interest as a treatment for NTG. 
 New molecules have also been tested on murine models. Dock3 (Dedicator of 
cytokinesis 3) is a molecule found to promote axon regeneration following optic 
nerve injury. Dock3 overexpression prevents glaucomatous retinal degeneration by 
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suppressing both NR2B-mediated glutamate neurotoxicity and oxidative stress in 
GLAST KO mice. Dock3 signalling pathway comes across as a potential therapeutic 
target for both neuroprotection and axonal regeneration in glaucoma (Namekata et al., 
2013). 
 
 Conclusion 
 
 There is still much to be understood concerning the topic of NTG. Further 
investigation is necessary regarding the physiopathological mechanisms behind this 
ophthalmic disease. 
 Some questions still remain. What explains the difference in incidence 
between Japan and Korea and western countries? Is NTG under-diagnosed in Europe 
and America? Should glaucomatous damage be searched for in patients with sleep 
apneia or migraines? What about in patients with autoimmune diseases? 
 What seems certain is that new treatments that may arise from investigation in 
NTG patients may present as further therapeutic options in patients with other types 
of glaucoma, as new studies are focusing on the approach to the damage in the optic 
nerve itself.  
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